Researchers from HKUMed discovered the mechanisms of how infection with SARS-CoV-2 virus can lead to lung injury and vascular damage. The study is the first to demonstrate such mechanism. The research team found that Imatinib, an FDA-approved drug, may work as a potential treatment for COVID-19 induced vascular diseases by modulating the dysregulated immune responses induced by SARS-CoV-2 in endothelial cells.